Literature DB >> 16472359

Prepulse inhibition of acoustic startle response in mild cognitive impairment and mild dementia of Alzheimer type.

Akinori Ueki1, Kyoko Goto, Noriko Sato, Hiroyuki Iso, Yoshio Morita.   

Abstract

Amnestic mild cognitive impairment (MCI) describes the condition of memory-impaired individuals who otherwise function well and do not meet the clinical criteria for dementia. Such individuals are considered to represent a transitional stage between normal aging and dementia of Alzheimer type (DAT). Neurobiologic changes in amnestic MCI, and their significance for psychophysiologic function, are poorly understood. In this study, the authors compared acoustic prepulse inhibition (PPI) between subjects with amnestic MCI and mild DAT to characterize sensorimotor gating. The acoustic startle reflex, which the authors measured using an accelerometer and electromyogram, involves whole-body movement and eye blink in response to a sudden loud noise (115 dB). PPI is inhibition of this reflex by a softer noise (prepulse; 85 dB) preceding the startle stimulus by 30 ms. PPI was examined in 30 controls, 20 subjects with amnestic MCI, and 20 subjects with mild DAT. Neither amnestic MCI nor mild DAT affected startle movement amplitude. Subjects with amnestic MCI showed significantly enhanced PPI (gating facilitation), while subjects with mild DAT exhibited significantly less PPI than controls (gating deficit). This pattern of PPI changes suggests that neuropathologic changes in the limbic cortex, mainly the entorhinal cortex, at the earliest stage of DAT might be responsible for PPI abnormalities via disturbed regulation of the limbic cortico-striato-pallido-pontine circuitry. Startle PPI changes could be used as a biologic marker for amnestic MCI and mild DAT.

Entities:  

Mesh:

Year:  2006        PMID: 16472359     DOI: 10.1111/j.1440-1819.2006.01460.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  27 in total

Review 1.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

2.  Skin Conduction Levels Differentiate Frontotemporal Dementia From Alzheimer's Disease.

Authors:  Mario F Mendez; Sylvia S Fong; Mark M Ashla; Elvira E Jimenez; Andrew R Carr
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2018-04-06       Impact factor: 2.198

3.  Arousal and the control of perception and movement.

Authors:  E Garcia-Rill; T Virmani; J R Hyde; S D'Onofrio; S Mahaffey
Journal:  Curr Trends Neurol       Date:  2016

4.  Gestational Stress Augments Postpartum β-Amyloid Pathology and Cognitive Decline in a Mouse Model of Alzheimer's Disease.

Authors:  Zahra Jafari; Jogender Mehla; Bryan E Kolb; Majid H Mohajerani
Journal:  Cereb Cortex       Date:  2019-08-14       Impact factor: 5.357

5.  Individual difference in prepulse inhibition does not predict spatial learning and memory performance in C57BL/6 mice.

Authors:  Daria Peleg-Raibstein; Singer Philipp; Joram Feldon; Benjamin K Yee
Journal:  Cogn Affect Behav Neurosci       Date:  2015-12       Impact factor: 3.282

6.  Diagnostic and prognostic biomarkers for HAND.

Authors:  Kristen A McLaurin; Rosemarie M Booze; Charles F Mactutus
Journal:  J Neurovirol       Date:  2019-01-03       Impact factor: 2.643

7.  Acetylcholine receptor and behavioral deficits in mice lacking apolipoprotein E.

Authors:  Jessica A Siegel; Theodore S Benice; Peter Van Meer; Byung S Park; Jacob Raber
Journal:  Neurobiol Aging       Date:  2009-01-28       Impact factor: 4.673

8.  Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patients.

Authors:  L Elliot Hong; Ikwunga Wonodi; Jada Lewis; Gunvant K Thaker
Journal:  Neuropsychopharmacology       Date:  2007-10-24       Impact factor: 7.853

9.  Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimer's disease.

Authors:  J-M Zhuo; G S Portugal; W D Kruger; H Wang; T J Gould; D Pratico
Journal:  Curr Alzheimer Res       Date:  2010-03       Impact factor: 3.498

Review 10.  Neurophysiological biomarkers for drug development in schizophrenia.

Authors:  Daniel C Javitt; Kevin M Spencer; Gunvant K Thaker; Georg Winterer; Mihály Hajós
Journal:  Nat Rev Drug Discov       Date:  2008-01       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.